Back to discover
Disease

Gout

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHGout
4
Publications
19
Clinical trials
1
Related conditions
12
Associated genes
12
Related proteins
2024
Latest publication
Current focus
Pro-neuregulin-1 biologyTherapeutic developmentXanthine dehydrogenase/oxidase biologyInflammation & immunityMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
  • 5 industry developments reported.
Upcoming Milestones
Clinical Milestones10View all 10
Results posted 2
Results expected 4
Recently completed 3
Other updates 1
+2 more in the activity timeline below
Industry & Market5View
Activity timeline15

Clinical trials

13 sponsors · 2 new · 3 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
16
Late-stage
6
Completed
Late-stage studies

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial

Phase 4 · Recruiting · Massachusetts General Hospital

A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout

Phase 3 · Recruiting · Amgen

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout

Phase 3 · Recruiting · Crystalys Therapeutics

SAVE-Care (SGLT2i As Novel Gout Care) Trial

Phase 4 · Recruiting · Massachusetts General Hospital

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Phase 2/3 · Recruiting · Olatec Therapeutics, Inc.

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

Phase 3 · Active, not recruiting · Arthrosi Therapeutics
Recruiting

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial

Phase 4 · Recruiting · Massachusetts General Hospital

A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout

Phase 3 · Recruiting · Amgen

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout

Phase 3 · Recruiting · Crystalys Therapeutics

SAVE-Care (SGLT2i As Novel Gout Care) Trial

Phase 4 · Recruiting · Massachusetts General Hospital

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Phase 2/3 · Recruiting · Olatec Therapeutics, Inc.
Recently completed

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

Phase 3 · Completed · Arthrosi Therapeutics

A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks Compared With KRYSTEXXA Administered Every 2 Weeks With Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants With Uncontrolled Refractory Gout (FORWARD II)

Phase 4 · Completed · Amgen

Safety & Efficacy of Genakumab in Patients With Frequent Flares

Phase 3 · Completed · Changchun GeneScience Pharmaceutical Co., Ltd.

A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

Phase 3 · Completed · JW Pharmaceutical

A Phase 4, Multicenter, Open-Label, Infusion Duration Study To Assess Safety, Tolerability and Efficacy of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Phase 4 · Completed · Amgen

A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks With Co-Administration of Weekly Doses of Methotrexate in Patients With Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)

Phase 4 · Completed · Amgen

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2020–2024
Major themes8
  • Gout3
  • Hyperuricemia2
  • Arthritis, Gouty1
  • Dysbiosis1
  • Gastrointestinal Microbiome1
  • Global Burden of Disease1
  • Prebiotics1
  • Probiotics1
Leading journals4
  • Arthritis & rheumatology (Hoboken, N.J.)1
  • Frontiers in immunology1
  • Lancet (London, England)1
  • World journal of gastroenterology1
Leading researchers8
  • Li C2
  • Chen X1
  • Cui L1
  • Dalbeth N1
  • Deng Y1
  • Durairajan SSK1
  • Fu X1
  • Hu S1
Affiliations (unnormalised)6
  • California and University of California San Diego1
  • CAS Key Laboratory of Nutrition1
  • Center for Excellence in Post-Harvest Technologies1
  • Guizhou Provincial People's Hospital1
  • Karpagam Academy of Higher Education1
  • Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SLC22A120.79ABCG20.71XDH0.70SLC22A110.66PTGS20.63PTGS10.61SLC2A90.60TUBA1B0.59ADH1B0.57SLC16A90.57IL1RN0.56PNPLA30.55

Disease biology

12 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Xanthine dehydrogenase/oxidasevia XDH0.70Solute carrier family 22 member 11via SLC22A110.66Prostaglandin G/H synthase 2via PTGS20.63Prostaglandin G/H synthase 1via PTGS10.61Tubulin alpha-1B chainvia TUBA1B0.59Interleukin-1 receptor antagonist proteinvia IL1RN0.56Organic anion transporter 3via SLC22A80.53Solute carrier family 22 member 6via SLC22A60.53Interleukin-1 betavia IL1B0.52Mitogen-activated protein kinase 10via MAPK100.51Insulin-like growth factor 1 receptorvia IGF1R0.50Pro-neuregulin-1, membrane-bound isoformvia NRG10.47

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Hyperuricemia2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.

Identifiers
MeSHGout
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.